$1.41
1.81%
Nasdaq, Apr 21, 08:41 pm CET
ISIN
US52886N4060
Symbol
LEXX

Lexaria Bioscience Corp Stock price

$1.38
-0.09 5.93% 1M
-1.45 51.24% 6M
-0.72 34.29% YTD
-0.96 41.03% 1Y
-2.67 65.93% 3Y
-7.92 85.16% 5Y
-2.03 59.52% 10Y
Nasdaq, Closing price Thu, Apr 17 2025
-0.02 1.43%
ISIN
US52886N4060
Symbol
LEXX
Industry

Key metrics

Market capitalization $24.23m
Enterprise Value $17.43m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 32.89
P/S ratio (TTM) P/S ratio 45.72
P/B ratio (TTM) P/B ratio 3.37
Revenue (TTM) Revenue $530.00k
EBIT (operating result TTM) EBIT $-9.28m
Free Cash Flow (TTM) Free Cash Flow $-7.45m
Cash position $6.54m
EPS (TTM) EPS $-0.58
P/E forward negative
P/S forward 53.14
EV/Sales forward 38.22
Short interest 4.36%
Show more

Is Lexaria Bioscience Corp a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,780 stocks worldwide.

Lexaria Bioscience Corp Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Lexaria Bioscience Corp forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Lexaria Bioscience Corp forecast:

Buy
100%

Financial data from Lexaria Bioscience Corp

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Feb '25
+/-
%
0.53 0.53
56% 56%
100%
- Direct Costs 0.09 0.09
55% 55%
17%
0.44 0.44
214% 214%
83%
- Selling and Administrative Expenses 4.46 4.46
32% 32%
842%
- Research and Development Expense 5.18 5.18
47% 47%
977%
-9.20 -9.20
36% 36%
-1,736%
- Depreciation and Amortization 0.08 0.08
47% 47%
15%
EBIT (Operating Income) EBIT -9.28 -9.28
35% 35%
-1,751%
Net Profit -9.38 -9.38
36% 36%
-1,770%

In millions USD.

Don't miss a Thing! We will send you all news about Lexaria Bioscience Corp directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Lexaria Bioscience Corp Stock News

Neutral
Accesswire
18 days ago
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss KELOWNA, BC / ACCESS Newswire / April 3, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the "Study") underway in Australia. Enrollment o...
Neutral
TheNewswire
18 days ago
Registered Phase-1b 12-week study investigating safety, diabetes control, and weight loss    Kelowna, British Columbia – April 3, 2025 – TheNewswire - Lexaria Bioscience Corp. (NASDAQ:LEXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to provide this progress update on its Phase 1b, 12-week chronic study GLP-1-H24-4 (the “ Study ”) underway in Australia.
Neutral
Accesswire
19 days ago
Head-to-head human study comparing traditional injected liraglutide to first-ever oral DehydraTECH-liraglutide Study will investigate Pharmacokinetics and Safety KELOWNA, BC / ACCESS Newswire / April 2, 2025 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, is pleased to announce that dosing has begun as scheduled...
More Lexaria Bioscience Corp News

Company Profile

Lexaria Bioscience Corp. is a proprietary drug delivery technology company. Its technology DehydraTECH, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption, reduces time of onset, and masks unwanted tastes for orally administered bioactive molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products; and to a tobacco producer for the development of smokeless, oral-based nicotine products. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Head office United States
CEO Richard Christopher
Employees 7
Founded 2004
Website www.lexariabioscience.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today